Skip to main content

Vaccine-induced neutralizing antibodies directed in part to the simian immunodeficiency virus (SIV) V2 domain were unable to protect rhesus monkeys from SIV experimental challenge.

Publication ,  Journal Article
Schlienger, K; Montefiori, DC; Mancini, M; Rivière, Y; Tiollais, P; Michel, ML
Published in: J Virol
October 1994

The potential of the simian immunodeficiency virus (SIV) variable 2 (V2) domain as an effective region to boost SIV-neutralizing antibodies and to protect against live SIV challenge was tested in rhesus macaques. In this study, two rhesus macaques were primed with vaccinia virus recombinants expressing the surface glycoprotein gp140 of SIVmac and were given booster injections with the SIVmac V2 domain presented by a highly immunogenic carrier, the hepatitis B surface antigen (HBsAg). The two vaccinated macaques exhibited SIV-neutralizing antibodies after primer injections that were enhanced by the V2/HBsAg injections. Part of these SIV-neutralizing antibodies were directed specifically to the V2 region, as shown by neutralization-blocking experiments. However, despite having consistent SIV-neutralizing antibody titers, animals were not protected against homologous challenge with BK28, the molecular clone of SIVmac251. No SIV envelope-specific cellular cytotoxic response was detected throughout the immunization protocol, suggesting that neutralizing antibodies directed to SIV envelope gp140 and especially to the V2 domain were unable on their own to protect against SIV challenge. Furthermore, the vaccinees seemed to have higher viral loads than control animals after challenge, raising the question of whether neutralizing antibodies induced by vaccination and directed to the SIV envelope selected viral escape mutants, as shown previously in SIV-infected macaques. This mechanism is certainly worthy of intensive investigation and raises some concern for SIV envelope-targeted immunization.

Duke Scholars

Published In

J Virol

DOI

ISSN

0022-538X

Publication Date

October 1994

Volume

68

Issue

10

Start / End Page

6578 / 6588

Location

United States

Related Subject Headings

  • Virology
  • Viral Vaccines
  • Vaccines, Synthetic
  • Simian immunodeficiency virus
  • Simian Immunodeficiency Virus
  • Simian Acquired Immunodeficiency Syndrome
  • Recombinant Proteins
  • Neutralization Tests
  • Molecular Sequence Data
  • Macaca mulatta
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Schlienger, K., Montefiori, D. C., Mancini, M., Rivière, Y., Tiollais, P., & Michel, M. L. (1994). Vaccine-induced neutralizing antibodies directed in part to the simian immunodeficiency virus (SIV) V2 domain were unable to protect rhesus monkeys from SIV experimental challenge. J Virol, 68(10), 6578–6588. https://doi.org/10.1128/JVI.68.10.6578-6588.1994
Schlienger, K., D. C. Montefiori, M. Mancini, Y. Rivière, P. Tiollais, and M. L. Michel. “Vaccine-induced neutralizing antibodies directed in part to the simian immunodeficiency virus (SIV) V2 domain were unable to protect rhesus monkeys from SIV experimental challenge.J Virol 68, no. 10 (October 1994): 6578–88. https://doi.org/10.1128/JVI.68.10.6578-6588.1994.
Schlienger, K., et al. “Vaccine-induced neutralizing antibodies directed in part to the simian immunodeficiency virus (SIV) V2 domain were unable to protect rhesus monkeys from SIV experimental challenge.J Virol, vol. 68, no. 10, Oct. 1994, pp. 6578–88. Pubmed, doi:10.1128/JVI.68.10.6578-6588.1994.

Published In

J Virol

DOI

ISSN

0022-538X

Publication Date

October 1994

Volume

68

Issue

10

Start / End Page

6578 / 6588

Location

United States

Related Subject Headings

  • Virology
  • Viral Vaccines
  • Vaccines, Synthetic
  • Simian immunodeficiency virus
  • Simian Immunodeficiency Virus
  • Simian Acquired Immunodeficiency Syndrome
  • Recombinant Proteins
  • Neutralization Tests
  • Molecular Sequence Data
  • Macaca mulatta